Xarah Fe Kit
Product Images NDC 70700-310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Xarah Fe (NDC 70700-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (Image 01)

Structural Formula (Image 01)
Chemical structure of norethindrone acetate and chemical structure of ethinyl estradiol, the active ingredients in XARAH FE tablets. Each structure shows the molecular arrangement and chemical bonds for their respective compound.*
FDA Label Image

Concentrations (Image 02)

Concentrations (Image 02)
Two line graphs showing mean plasma concentrations of ethinyl estradiol and norethindrone over time in hours. The top graph depicts mean plasma ethinyl estradiol concentrations (pg/mL) for three groups (1/20, 1/30, 1/35) from 0 to 24 hours. The bottom graph shows mean plasma norethindrone concentrations (ng/mL) for the same three groups over the same time period.*
FDA Label Image

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)
A line graph comparing the mean percent reduction in lesion counts over six cycles between a placebo group and a group receiving norethindrone acetate, ethinyl estradiol, and ferrous fumarate tablets. The graph shows higher reduction percentages for the active treatment group compared to placebo, with data points plotted from baseline through cycle 6.*
FDA Label Image

Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)

Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)
A bar chart depicting mortality rate per 100,000 women users across different age groups (15–24, 25–34, 35–44, 45). The chart compares four groups: ever-users (non-smokers), ever-users (smokers), controls (non-smokers), and controls (smokers) with distinct shading patterns for each group.*
FDA Label Image

Blister (Image 05)

Blister (Image 05)
A dosing schedule guide for norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate, showing a 28-tablet layout arranged by day of the week and divided into 4 weeks. Instructions include starting on Sunday for starters or adjusting with a day label for Day-1 starters. It notes the tablet strengths and includes a direction to take pills from left to right.*
FDA Label Image

Blister (Image 06)

Blister (Image 06)
An instructional diagram showing the weekly tablet schedule for a medication kit. It outlines a 28-day pill cycle across four weeks, with each week displaying seven circles representing daily tablets from Sunday to Saturday. Arrows indicate the direction to take the pills from left to right over each week. There is guidance for 'Day-1 Starters' on when to place a day label sticker according to the first day of the period. The diagram includes the drug components norethindrone acetate, ethinyl estradiol, and ferrous fumarate, with dosage details and a note that ferrous fumarate tablets are not USP for dissolution and assay.*
FDA Label Image

3s Carton (Image 07)

3s Carton (Image 07)
XARAH FE kit packaging label for tablets containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate. The label displays strengths of 1 mg norethindrone acetate with varying mcg of ethinyl estradiol (20, 30, 35) and highlights a 28-day regimen with 3 pouches containing 28 tablets. The labeler shown is Xiromed LLC, with manufacturing by Mylan Pharmaceuticals Inc.*
FDA Label Image

Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)

Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)
A forest plot chart displaying effect estimates (odds ratio/risk ratio) with confidence intervals from multiple studies related to contraceptive use. The studies are listed on the left by name and year, with effect estimates shown as points and lines on a horizontal axis ranging from -1.5 to 2, accompanied by numerical values on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.